A new drug called denosumab may soon give Zometa (zoledronic acid) competition as the standard of care in treating bone metastases in patients with advanced breast cancer. Patients taking denosumab ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback